Aspirin Bioactivity for Prevention of Cardiovascular Injury in COVID-19.

Diaz, Temistocles; Trachtenberg, Barry H; Abraham, Samuel J K; KosagiSharaf, Rao; Durant-Archibold, Armando A

Diaz, Temistocles; Trachtenberg, Barry H; Abraham, Samuel J K; KosagiSharaf, Rao; Durant-Archibold, Armando A.

Afiliação

Diaz T; Internal Medicine-Interventional Cardiology, Department of Cardiology, Punta Pacifica Hospital, Affiliate of John Hopkins Medicine International, Panama City, Panama.
Trachtenberg BH; Biomedicine Research Unit, Center for Biodiversity and Drug Discovery, Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT Asociation of Public Interest), Panama City, Panama.
Abraham SJK; Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, United States.
KosagiSharaf R; Department of Surgery & Centre for Advancing Clinical Research (CACR), Yamanashi University, Chuo, Japan.
Durant-Archibold AA; Edogawa Evolutionary Laboratory of Science (EELS), Edogawa Hospital, Tokyo, Japan.

Front Cardiovasc Med ; 7: 562708, 2020.

Article em En | MEDLINE | ID: mdl-33330639

Palavras-chave

COVID-19; SARS-CoV-2; aspirin; molecular mechanisms; prevention of cardiovascular disease

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Panamá